Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma

Nicola Silvestris, V. Longo, Francesco Cellini, Michele Reni, Alessandro Bittoni, Ivana Cataldo, Stefano Partelli, Massimo Falconi, Aldo Scarpa, Oronzo Brunetti, Vito Lorusso, Daniele Santini, Alessio Giuseppe Morganti, Vincenzo Valentini, Stefano Cascinu

Research output: Contribution to journalArticlepeer-review


Treatment of pancreatic ductal adenocarcinoma (PDAC) is increasingly multidisciplinary, with neoadjuvant strategies (chemotherapy, radiation, and surgery) administered in patients with resectable, borderline resectable, or locally advanced disease. The rational supporting this management is the achievement of both higher margin-negative resections and conversion rates into potentially resectable disease and in vivo assessment of novel therapeutics. International guidelines suggest an initial staging of the disease followed by a multidisciplinary approach, even considering the lack of a treatment approach to be considered as standard in this setting. This review will focus on both literature data supporting these guidelines and on new opportunities related to current more active chemotherapy regimens. An analysis of the pathological assessment of response to therapy and the potential role of target therapies and translational biomarkers and ongoing clinical trials of significance will be discussed.

Original languageEnglish
Pages (from-to)309-324
Number of pages16
JournalCritical Reviews in Oncology/Hematology
Publication statusPublished - Feb 1 2016


  • Borderline
  • Chemotherapy
  • Locally advanced
  • Neoadjuvant
  • Pancreatic ductal adenocarcinoma
  • Radiotherapy
  • Target therapy

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology


Dive into the research topics of 'Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma'. Together they form a unique fingerprint.

Cite this